SCHEMBL6419710

SCHEMBL6419710

NN=C(c1ccc(-c2cccc(C(N)=O)c2)o1)c1nc2nonc2nc1Nc1ccc(F)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.40
TP53 P04637 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
BIRC5 O15392 1/20 0.38
SLC9A1 P19634 2/20 0.38
PIK3CA P42336 1/20 0.36
NR4A1 P22736 1/20 0.35
NR4A2 P43354 1/20 0.35
NR4A3 Q92570 1/20 0.35
SYK P43405 2/20 0.34
BTK Q06187 2/20 0.34
PTPN1 P18031 1/20 0.34
KDR P35968 2/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
POLB P06746 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6434895 0.93 BIRC5 (0.45) MAPTTP53SMN1; SMN2BIRC5SLC9A1
SCHEMBL6415907 0.92 BIRC5 (0.41) MAPTBIRC5SLC9A1PIK3CASYK
SCHEMBL6415096 0.90 AURKA (0.38) MAPTTP53SMN1; SMN2BIRC5SLC9A1
SCHEMBL6416017 0.88 KDR (0.38) MAPTTP53SMN1; SMN2BIRC5SLC9A1
SCHEMBL6413428 0.86 BIRC5 (0.47) MAPTSMN1; SMN2BIRC5NPC1RAB9A
SCHEMBL6419745 0.84 PTPN1 (0.43) MAPTTP53SMN1; SMN2SLC9A1PTPN1
SCHEMBL6415959 0.83 BIRC5 (0.42) MAPTBIRC5RAB9AKDM4EALDH1A1
SCHEMBL6432662 0.82 LDHA (0.40) MAPTBIRC5KDM4EALDH1A1POLB
SCHEMBL6419747 0.82 BIRC5 (0.43) MAPTTP53SMN1; SMN2BIRC5RAB9A
SCHEMBL6433045 0.82 KDM4E (0.45) MAPTTP53SMN1; SMN2SYKPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 MAPT 4420/4885TP53 4485/4885SMN1; SMN2 4369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.